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Introduction
Chromosomal aberrations constitute a hallmark of a cancer genome. Recurrent balanced chromosomal abnormalities, for example, those occurring in distinct types of leukemia or lymphoma, can be diagnostic and often explain pathogenesis of these conditions. Chromosomal defects also constitute excellent clonal markers, essential for the diagnosis of a malignant clone, or for the detection of minimal residual disease or relapse, especially in cancers arising in the hematopoietic system (1) (2) (3) . By contrast, the frequent complexity of chromosomal defects and inability to obtain viable cells, makes the diagnostic application of cytogenetic testing in solid tumors more difficult. Consequently, fewer chromosomal defects that can function as diagnostic or prognostic markers have been identified, although this has begun to change in recent years. Loss of heterozygosity (LOH) owing to segmental or numerical chromosomal deletion has been of particular importance and forms part of a number of paradigms of malignant transformation, including the concept of tumor suppressor gene inactivation and the Knudson two-hit hypothesis (4) . After the loss of chromosomal materials containing one allele, the remaining allele can be affected by somatic mutation or harbor a disease-prone polymorphic variant. Similarly, loss of chromosomal material can lead to LOH and conversion of heterozygous inherited (potentially functionally silent) mutation to a hemizygous mutation. However, the discovery of uniparental disomy (UPD), also referred to as copy-neutral LOH, has indicated that LOH may not be necessarily due to loss of chromosomal material. Under normal circumstances, 2 copies (paternal and maternal) of each autosome exist that carry discrete differences encoded by single nucleotide polymorphisms (SNPs) and can thereby be distinguished. In regions of UPD, portions of one of the chromosomes are lost and replaced by the exact copy of the remaining chromosome (either paternal or maternal) resulting in retention of two copies of genetic information but loss of polymorphic differences which existed due to the presence of maternal and paternal genes in this region of a diploid chromosome set. Due to the lack of copy number change, UPD remains undetected by metaphase cytogenetics. However, the widespread use of microsatellite analysis or genotyping sequential SNPs combined with copy number determination has shown that various types of UPD frequently occur in the cancer genome (5, 6) . Consequently, in this review we discuss the genesis and types of UPD seen in malignant and normal cells; we focus on mechanisms of selective growth advantage that can result from this lesion and discuss their mechanistic role in cancer pathogenesis. We also review the recurrent regions of UPD identified in various forms of cancer and the clinical implications associated with these defects.
Genetic and genomic implications of UPD
LOH due to loss of chromosomal material versus UPD. Until recently, LOH has been most consistently linked to deletions of chromosomal material in somatic cytogenetic defects encountered in cancer. In contrast, UPD has been identified through the study of inherited diseases as UPD can occur as a germ line lesion leading to isodisomy. Heterodisomy, another possible outcome of germ line UPD, does not result in LOH (7) . Inherited UPD was first described by Engel (8) and can affect whole chromosomes or fragments of chromosomes, where UPD can be interstitial or telomeric (Fig. 1) .
Principally, UPD corresponds to a duplication of either paternal (unipaternal disomy) or maternal (unimaternal disomy) alleles and thereby homozygosity for germ line allelic variants. Consequently, LOH due to deletion results in hemizygosity, while UPD results in homozygosity (Fig. 1) . Theoretically, it is also possible that trisomy is associated with LOH in form of uniparental trisomy, which is invariably related to numerical aberrations (Fig. 1) . Conceptually, any trisomy might represent a form of UPD without LOH as the both parental alleles are retained while one is duplicated.
Unlike constitutional UPD, the genesis of somatic UPD is not well understood but might be a result of mitotic recombination or a successful attempt to correct loss of chromosomal material through the duplication of the remaining allele (Fig. 2) .
The mechanics of UPD. The chromosomal mechanics behind UPD have been intensely investigated in embryology and inherited conditions. In consanguineous populations, homozygosity is frequent and can accumulate in the form of stretches of autozygosity. Although such changes do not always result in pathology, autozygosity represents a risk for inherited disease, including genetic predisposition to various cancers (9) . In contrast to autozygosity, germ line UPD can arise as a result of mistakes in meiosis, in which all cells in the organism contain the change or in the initial mitoses after fertilization resulting in tissue mosaicism. Autozygosity and meiotic UPD are not distinguishable without pedigree analysis (Fig. 3) . Germ line UPD can be due to meiotic chromosomal mis-segregation and subsequent mitotic re-assortment leading to a balanced genome. Various scenarios can lead to germ line meiotic UPD and heterodisomy and isodisomy (resulting in LOH) have to be distinguished from numerical chromosomal defects. Trisomic rescue following errors in meiosis I or II can result in UPD as one of the possible outcomes ( Fig. 3) (10) .
Unlike germ line UPD and autozygosity, somatic UPD results from mitotic homologous recombination events or represents an attempt to correct the unbalanced loss of chromosomal material by using the remaining alleles as a template (Fig. 2) . Numerical somatic UPD can occur due to mitotic errors including non-disjunction or loss of a chromosome due to anaphase lag followed by reduplication mechanism would be more difficult to invoke for segmental interstitial UPD as it would require 2 consecutive or simultaneous homologous recombination steps. It is possible that segmental UPD could also be a result of initial deletion followed by a compensatory reduplication of the remaining chromosomal fragment (Fig. 2 and 3 ). For diagnostic and investigational purposes the distinction between a somatic, clonal UPD and germ line UPD or autozygosity is of the utmost importance.
UPD and cancer
Specific chromosomal regions affected by UPD in cancer. The pivotal description of UPD in a hematological malignancy was reported in polycythemia vera (PV) (14) , in which UPD9p was found in 33% of patients, constituting the most common chromosomal lesion in this disease (15) . Later this chromosomal defect was linked to JAK2V617F mutation (16) . More comprehensive studies demonstrated that JAK2V617F mutations with UPD9p can also be found in other MPN (17, 18) . For example, primary myelofibrosis (PMF) reveales a high frequency of UPD9p with JAK2V617F mutations (44%) (19) . However, the homozygous mutational burden varies, because of differences in population size of mutant cells. Even in purified myeloid cell populations, heterozygous and homozygous cells can be found. Moreover, patients with essential thrombocytosis (ET) exhibit lower frequency of UPD9p and the resultant JAK2V617F mutational burden in ET is low compared with PMF and PV (16, 20) .
Systemic application of SNP arrays as a karyotyping tool ( (Table 1) .
Tumor-specific recurrent regions of UPD can be mapped for AML and MDS for example ( 
Predisposition to UPD in cancer.
That certain cancers display a higher frequency of somatic UPD, such as MUTYH-associated polyposis colon carcinomas (24) , and also can accumulate multiple areas of UPD (complex UPD) implies that there is an inherited or acquired predisposition to this type of defect owing to the presence of fragile sites prone to recombination or a specific type of chromosomal instability, for example. For some malignancies, particularly high frequencies of somatic UPD have been described, suggesting that this type of defect may be related to pathological pathways common in some but absent in other cancers. For instance, in sporadic colon cancer, physical loss of chromosomal material is characteristic and UPD is less common (25) .
Preferred sites of mitotic recombination leading to UPD have been identified, with a clustering of the centromeric and telomeric breakpoints (12) . In mantle cell lymphoma (MCL) the breakpoints flanking all the genomic UPDs were significantly associated with genomic regions enriched in copy number variants and segmental duplications, suggesting that the recombination at these regions might play a role in the genomic instability of MCL (26) . Similarly, a careful analysis of the sites of acquired UPD origin in low-risk MDS showed that 43% of UPD regions were localized to or as part of a previously identified fragile site (27) . Fragile sites correspond to known locations of frequent genomic instability and are associated with breakpoints occurring in the generation of chromosomal aberrations in hematological malignancies (28) . Fragile sites have also been associated with regulatory micro RNA amplifications and deletions (29) .
Risk factors for the acquisition of UPD also include the presence of BRCA mutations, which were shown to be associated with an increased frequency of UPD not observed in cases of spontaneous breast cancer (30) . In ovarian cancer, UPD was frequently observed in tumors with an inherited BRCA mutation (31) . Microsatellite instability (MSI) has been shown to be associated with the increased frequency of UPD (32) . MSI was present in 60% of patients with AML that had regions of UPD (Fig. 5) , whereas single locus MSI was absent in patients with AML in whom UPD was not detected (33) .
Pathogenic consequences of UPD in cancer.
Although it is likely that chromosomal deletions occur randomly, those resulting in a proliferative advantage or resistance to physiological apoptosis for example, could initiate clonal outgrowth. Selection for clones with a specific region of LOH could be related to a somatic or germ line loss of a wild type allele resulting in hemizygosity for an SNP-encoded disease-prone allele or a somatic or germ line mutated allele (Fig. 1) . If the affected area includes promoters of alleles that are differentially silenced (imprinted), deletion can lead to either a gain of imprinting (GOI) or loss of imprinting (LOI). This can result in changes in gene expression. UPD can also lead to the duplication of an imprinted expressed allele or a silenced (methylated), imprinted allele. In cases where the transcription of both alleles is required for normal cellular physiology, deletions can result in pathological haploinsufficiency and thereby LOH is less likely to play a pathogenic role (Fig. 1) .
Research. 
There are similarities and important differences between the consequences of LOH due to deletion or UPD. UPD could convey a permissive growth advantage when, in accordance with the 2-hit hypothesis, an initial heterozygous mutation is duplicated through UPD. This might result in homozygosity of a somatic mutation that inactivates a tumor suppressor gene, such as occurs in TP53 in UPD17p, RUNX1 in UPD21q and many others (Fig. 6) . Activating oncogenic mutations can be duplicated through UPD leading to increased proliferative drive though a double dose of the mutated gene product.
Such a scenario has been encountered with JAK2 (UPD9p) (14, 16, 34) , FLT3 internal tandem duplication (ITD) (UPD13q) (35, 36) , WT1 (UPD11p) (37, 38) and MPL (UPD1p) (19, 39) . Recently, we and other groups found loss of function mutations of EZH2, encoding trimethyltransferase of H3K27, in the patients with UPD7q (Fig. 6) (40-42) . Because methylation of H3K27 is a histone repressive mark associated with condensation of chromatin, its loss of function mutation results in chromatin relaxation and accelerating gene transcriptions, for example, WNT1 and HOXA family genes. EZH2 mutations are more commonly homozygous (UPD7q) than heterozygous (40, 42) . In myeloid malignancies, UPD is frequently observed on chromosome 11q specifically in MDS/MPN phenotype. CBL mutations were observed in 76% of the patients with UPD11q, however relatively rare (<5%) in the patients with deletion or without LOH 11q. In mutations associated with recurrent UPD, homozygosity might provide malignant clone with further growth advantage. Theoretically, a similar effect could be produced by LOH as a result of deletion, but for some genes, such as CBL, most mutations are homozygous and corresponding deletions were not found to harbor hemizygous mutations (22, 43, 44) . Consequently, CBL knock out is less leukemogenic than ring finger domain mutant knock in CBL null mice (43, 45) . By contrast, TP53 or TET2 mutations are associated with both deletions and UPD. UPD can also affect germ line heterozygous mutations. Examples of such mutations include UPD11q and UPD17q leading to duplication of CBL and NF1 mutations in juvenile myelomonocytic leukemia (JMML) (Fig. 6) (46-48) .
Somatic UPD can also lead to duplication and thereby homozygosity of disease prone SNPs that are silent in a heterozygous configuration. Typically, such SNPs show an exceeding low frequency of homozygosity for the minor allele in the general population. Of note is that although duplication of initially heterozygous mutations is a driving force for clonal dominance, areas of UPD contain a large number of genes that can include germline polymorphisms and imprinted sites. For example, on chromosome 9p, which is frequently affected by UPD, CNTLN, KANK1, DMRT1, TOPORS and MLANA genes were reported to be either imprinted or differentially methylated. Therefore UPD at this site can lead to GOI and LOI for specific genes (49) (50) (51) (52) . In addition, UPD9p contains a large number of nonsynonymous polymorphisms for which either minor or major allele can be duplicated and result in discrete changes of the phenotype. These findings indicate that association of high allelic burden of JAK2V617F mutation due to UPD9p may be influenced by homozygous SNPs and/or loss or gain of expression of Examples of changes LOI and GOI can also be found cancer-prone inherited disorders associated with UPD: GOI of H19 and LOI of IGF2 (58, 59) . A similar alteration of imprinting patterns has been found in hepatoblastoma, a tumor characterized with frequent UPD11p affecting H19 and IGF2 (60) . LOI for IGF2 and H19 due to UPD is evident in colon carcinoma (61) and Wilms' tumor (62), ARH1 LOI is evident in ovarian and breast cancer (63) and H19 LOI is evident in AML (64) . Some of these events might be due to a shared mechanism of UPD. Thus, it is possible that although deletion or duplication can randomly affect each parental chromosome, clonal selection might favor the expressed or silenced imprinted allele and so might not be random. In MDS for example, the FZD9 promoter has been found to be consistently hypermethylated in patients with LOH7q as a result of UPD or chromosomal deletion (65) . Theoretically, several of these mechanisms can be operative in UPD affecting large number of genes and contributing to the heterogeneity of resulting tumor phenotype and clinical behavior (Fig. 6) .
Conclusions
UPD is a previously cryptic type of chromosomal aberration ubiquitously occurring in cancer and often mapping to the regions affected by loss of chromosomal material. During malignant evolution, the clonal selection process favors duplication of heterozygous somatic or germline mutations, disease-prone SNP alleles or imprinting patterns that can produce a selective advantage. Whole genome scanning technologies with SNP arrays greatly facilitated detection of UPD. In addition to the somatic form of UPD, stretches of homozygosity due to inherited UPD or autozygosity can be detected through SNP arrays necessitating the distinction of truly clonal events from non-clonal homozygosity. Inherited UPD or autozygosity might constitute an independent predisposition factor for the development of malignancy. 
